01896nas a2200349   4500000000100000008004100001260000900042653002900051653002000080653003000100653002100130653001100151653001900162653001100181653003000192653002300222653001200245653003900257653003300296653001400329653001500343653001300358653001700371100001400388700001400402700001200416245007300428300001100501490000700512520101300519022001401532       2007                            d  c200710aAnti-Inflammatory Agents10aDrug Resistance10aDrug Therapy, Combination10aErythema Nodosum10aFemale10aHIV Infections10aHumans10aHypersensitivity, Delayed10aLeprostatic Agents10aleprosy10aPeripheral Nervous System Diseases10aPractice Guidelines as Topic10aPregnancy10aRecurrence10aSteroids10aTuberculosis1 aSehgal VN1 aSardana K1 aDogra S00aManagement of complications following leprosy: an evolving scenario.  a366-740 v183 a<p>Reaction in leprosy, nerve damage/deformities, drug resistance/relapses, may come as yet another challenge. Their management too is intriguing and has been dealt with carefully. In addition, special situations such as pregnancy and concomitant HIV/tuberculosis also need care for their effective management. To facilitate a comprehensive appraisal, the subject has been bifurcated into management of leprosy per se were multidrug therapy (MDT) is widely the accepted and acclaimed treatment option. The former has been dealt with in depth in an adjoining article, while the latter forms the contents of the current paper. The salient contents of the text are illustrated by exemplary literature, which should provide an adequate and comprehensive source of information for the academic work force, under- and post-graduate students of dermatology, health workers and treating physicians involved in the care of leprosy patients, and facilitate decision making or options for treatment in a given case.</p>  a0954-6634